Rare
lephants
Screener
Toggle theme
C
C21 Investments Inc.
CWLXF
·
Healthcare, Drug Manufacturers - General
Financial Statements
Profitability
Balance Sheet
Cash Flow
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2026
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
Total Cash from Operations:
$2.0M
Line Item
Value
% of Total
Capital Expenditures
$244.8K
12.1%
Stock Repurchases
$103.0K
5.1%
Working Capital
$653.8K
32.4%
Other
$1.0M
50.3%
Net Cash Flow
$0
0.0%
Download CSV